220 related articles for article (PubMed ID: 37067901)
21. Identification and characterization of two novel germ line p53 mutations in the non-LFS/non-LFL breast cancer families in Chinese population.
Cao AY; Jin W; Shi PC; Di GH; Shen ZZ; Shao ZM
Breast Cancer Res Treat; 2010 Jan; 119(2):295-303. PubMed ID: 19238535
[TBL] [Abstract][Full Text] [Related]
22. The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube.
Xian W; Miron A; Roh M; Semmel DR; Yassin Y; Garber J; Oliva E; Goodman A; Mehra K; Berkowitz RS; Crum CP; Quade BJ
J Pathol; 2010 Jan; 220(1):17-23. PubMed ID: 19834951
[TBL] [Abstract][Full Text] [Related]
23. Li-Fraumeni syndrome: a p53 family affair.
Iwakuma T; Lozano G; Flores ER
Cell Cycle; 2005 Jul; 4(7):865-7. PubMed ID: 15917654
[TBL] [Abstract][Full Text] [Related]
24. DNA damage-associated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation.
Goi K; Takagi M; Iwata S; Delia D; Asada M; Donghi R; Tsunematsu Y; Nakazawa S; Yamamoto H; Yokota J; Tamura K; Saeki Y; Utsunomiya J; Takahashi T; Ueda R; Ishioka C; Eguchi M; Kamata N; Mizutani S
Cancer Res; 1997 May; 57(10):1895-902. PubMed ID: 9157982
[TBL] [Abstract][Full Text] [Related]
25. Several mutant p53 proteins detected in cancer-prone families with Li-Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53.
Srivastava S; Wang S; Tong YA; Pirollo K; Chang EH
Oncogene; 1993 Sep; 8(9):2449-56. PubMed ID: 8361758
[TBL] [Abstract][Full Text] [Related]
26. A functionally inactive p53 Li-Fraumeni syndrome mutant.
Hao M; Finlay CA; Lozano G
Oncogene; 1993 Feb; 8(2):299-306. PubMed ID: 8426739
[TBL] [Abstract][Full Text] [Related]
27. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis.
Hanel W; Marchenko N; Xu S; Yu SX; Weng W; Moll U
Cell Death Differ; 2013 Jul; 20(7):898-909. PubMed ID: 23538418
[TBL] [Abstract][Full Text] [Related]
28. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.
Olive KP; Tuveson DA; Ruhe ZC; Yin B; Willis NA; Bronson RT; Crowley D; Jacks T
Cell; 2004 Dec; 119(6):847-60. PubMed ID: 15607980
[TBL] [Abstract][Full Text] [Related]
29. Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo.
Xiong S; Chachad D; Zhang Y; Gencel-Augusto J; Sirito M; Pant V; Yang P; Sun C; Chau G; Qi Y; Su X; Whitley EM; El-Naggar AK; Lozano G
Cancer Res; 2022 May; 82(10):1926-1936. PubMed ID: 35320355
[TBL] [Abstract][Full Text] [Related]
30. RECQL4 and p53 potentiate the activity of polymerase γ and maintain the integrity of the human mitochondrial genome.
Gupta S; De S; Srivastava V; Hussain M; Kumari J; Muniyappa K; Sengupta S
Carcinogenesis; 2014 Jan; 35(1):34-45. PubMed ID: 24067899
[TBL] [Abstract][Full Text] [Related]
31. Towards an understanding of the role of p53 in adrenocortical carcinogenesis.
Wasserman JD; Zambetti GP; Malkin D
Mol Cell Endocrinol; 2012 Mar; 351(1):101-10. PubMed ID: 21930187
[TBL] [Abstract][Full Text] [Related]
32. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
[TBL] [Abstract][Full Text] [Related]
33. Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.
Zhou R; Xu A; Gingold J; Strong LC; Zhao R; Lee DF
Trends Pharmacol Sci; 2017 Oct; 38(10):908-927. PubMed ID: 28818333
[TBL] [Abstract][Full Text] [Related]
34. Genetic modeling of Li-Fraumeni syndrome in zebrafish.
Parant JM; George SA; Holden JA; Yost HJ
Dis Model Mech; 2010; 3(1-2):45-56. PubMed ID: 20075382
[TBL] [Abstract][Full Text] [Related]
35. Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome.
Kamihara J; Rana HQ; Garber JE
Hum Mutat; 2014 Jun; 35(6):654-62. PubMed ID: 24706533
[TBL] [Abstract][Full Text] [Related]
36. The tumor suppressor PTEN interacts with p53 in hereditary cancer (Review).
Nakanishi A; Kitagishi Y; Ogura Y; Matsuda S
Int J Oncol; 2014 Jun; 44(6):1813-9. PubMed ID: 24718924
[TBL] [Abstract][Full Text] [Related]
37. Unaffected Li-Fraumeni Syndrome Carrier Parent Demonstrates Allele-Specific mRNA Stabilization of Wild-Type
Buzby JS; Williams SA; Nugent DJ
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553570
[TBL] [Abstract][Full Text] [Related]
38. Amino-terminal p53 mutations lead to expression of apoptosis proficient p47 and prognosticate better survival, but predispose to tumorigenesis.
Phang BH; Othman R; Bougeard G; Chia RH; Frebourg T; Tang CL; Cheah PY; Sabapathy K
Proc Natl Acad Sci U S A; 2015 Nov; 112(46):E6349-58. PubMed ID: 26578795
[TBL] [Abstract][Full Text] [Related]
39. The function of a heterozygous p53 mutation in a Li-Fraumeni syndrome patient.
Li Y; Li T; Tang Y; Zhan Z; Ding L; Song L; Yu T; Yang Y; Ma J; Zhang Y; Zhou Y; Gu S; Xu M; Gao Y; Li Y
PLoS One; 2020; 15(6):e0234262. PubMed ID: 32516327
[TBL] [Abstract][Full Text] [Related]
40. Super-Transactivation TP53 Variant in the Germline of a Family with Li-Fraumeni Syndrome.
Id Said B; Kim H; Tran J; Novokmet A; Malkin D
Hum Mutat; 2016 Sep; 37(9):889-92. PubMed ID: 27297285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
